Evidence map›Paper›PMID 39819260›Full record

ArticleFuture oncology (London, England)2025

Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.

Ritu Salani, Tirza Areli Calderón Boyle, Jonathan Lim, Jeanne M Schilder, Jean A Hurteau, Jessica Perhanidis, Amanda Golembesky, Floor J Backes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ritu SalaniDepartment of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.ORCID 0000-0002-5646-343X
Tirza Areli Calderón BoyleGSK, Upper Providence, PA, USA.
Jonathan LimGSK, Upper Providence, PA, USA.ORCID 0009-0007-9139-8841
Jeanne M SchilderGSK, Philadelphia, PA, USA.
Jean A HurteauGSK, Waltham, MA, USA.
Jessica PerhanidisGSK, Waltham, MA, USA.ORCID 0000-0001-6943-8500
Amanda GolembeskyGSK, Durham, NC, USA.
Floor J BackesDivision of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Hospital Comprehensive Cancer Center, Columbus, OH, USA.ORCID 0000-0002-9225-6913

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo assess real-world progression-free survival (rwPFS) and time to next treatment (rwTTNT) among patients with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib monotherapy. PATIENTS &

methodsIn this US-nationwide, electronic health record-derived, deidentified database study, eligible patients with EOC initiated 1LM niraparib monotherapy (1 January 2017-1 December 2022) following first-line platinum-based chemotherapy. Median rwPFS and rwTTNT were estimated with Kaplan-Meier methodology overall and in a homologous recombination-deficient (HRd) subgroup (further stratified as

resultsObserved median rwPFS was 11.4 (95% CI, 10.1-12.7) months overall (

conclusionsThe real-world observed median rwPFS and rwTTNT were longer for patients with EOC who received 1LM niraparib monotherapy in the HRd subgroup (specifically for the

Indexed as

Carcinoma, Ovarian EpithelialIndazolesOvarian NeoplasmsPiperidinesPoly(ADP-ribose) Polymerase InhibitorsAdultAgedAged, 80 and overBRCA1 ProteinBRCA2 ProteinFemaleHumansMaintenance ChemotherapyMiddle AgedMutationProgression-Free SurvivalBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinIndazolesniraparibPiperidinesPoly(ADP-ribose) Polymerase InhibitorsEpithelial ovarian cancerfirst-line maintenanceniraparibprogression-free survivalreal-worldtime to next treatment

Identifiers

PMID39819260
PMCPMC11792861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.